Melanoma (Skin)

Oncology
12
Pipeline Programs
13
Companies
20
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
6
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
6 programs
3
everolimusPhase 24 trials
everolimusPhase 21 trial
sargramostimPhase 21 trial
Microsoft Band 2 + UV messagingN/A1 trial
Shade + app with messagingN/A1 trial
+1 more programs
Active Trials
NCT03518229Withdrawn0Est. May 2021
NCT03927742Completed368Est. Oct 2022
NCT00049010Completed314Est. Oct 2009
+6 more trials
Pfizer
PfizerNEW YORK, NY
1 program
1
CP-675,206Phase 21 trial
Active Trials
NCT00471887Completed32Est. Mar 2015
Immunocore
ImmunocoreOXFORDSHIRE, United Kingdom
1 program
1
TebentafuspPhase 21 trial
Active Trials
NCT05315258Active Not Recruiting850Est. Jun 2027
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
rubitecanPhase 21 trial
Active Trials
NCT00005875CompletedEst. Apr 2004
Sanofi
SanofiPARIS, France
2 programs
2
MART-1 antigenPhase 1/21 trial
aldesleukinPhase 1/21 trial
Active Trials
NCT00010309Unknown
NCT00004025Unknown36
Bristol Myers Squibb
2 programs
1
MART-1Phase 11 trial
French Clinical Datbase of Melanoma Patients (RIC-Mel)N/A
Active Trials
NCT01176461Completed127Est. Dec 2016
C
CureVacGermany - Tübingen
1 program
1
CV8102Phase 11 trial
Active Trials
NCT03291002UnknownEst. Feb 2023
Valo Therapeutics
1 program
1
PeptiCRAd-1Phase 11 trial
Active Trials
NCT05492682Active Not RecruitingEst. Dec 2026
Providence Therapeutics
1 program
1
gp100 antigenPhase 11 trial
Active Trials
NCT00091143CompletedEst. Mar 2010
Amgen
AmgenTHOUSAND OAKS, CA
1 program
French Clinical Datbase of Melanoma Patients (RIC-Mel)N/A1 trial
Active Trials
NCT03315468Recruiting16,000Est. Mar 2030
Roche
RocheSTAVANGER NORWAY, Norway
1 program
French Clinical Datbase of Melanoma Patients (RIC-Mel)N/A
Genomics
GenomicsUK - Oxford
1 program
mutation analysisN/A1 trial
Active Trials
NCT00346008Completed2,500Est. Feb 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Alliance Pharmaceuticalseverolimus
ImmunocoreTebentafusp
Alliance Pharmaceuticalseverolimus
Alliance Pharmaceuticalseverolimus
PfizerCP-675,206
Alliance Pharmaceuticalseverolimus
Alliance Pharmaceuticalssargramostim
Astex Pharmaceuticalsrubitecan
SanofiMART-1 antigen
Sanofialdesleukin
Valo TherapeuticsPeptiCRAd-1
CureVacCV8102
Alliance Pharmaceuticalseverolimus
Bristol Myers SquibbMART-1
Providence Therapeuticsgp100 antigen

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 20,422 patients across 20 trials

NCT03839940Alliance Pharmaceuticalseverolimus

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

Start: Jun 2019Est. completion: Aug 202239 patients
Phase 3Terminated
NCT05315258ImmunocoreTebentafusp

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Start: Jul 2022Est. completion: Jun 2027850 patients
Phase 2Active Not Recruiting
NCT01661283Alliance Pharmaceuticalseverolimus

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

Start: Sep 2012Est. completion: Dec 201725 patients
Phase 2Completed
NCT00521001Alliance Pharmaceuticalseverolimus

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery

Start: Jan 2008Est. completion: Dec 201049 patients
Phase 2Completed
NCT00471887PfizerCP-675,206

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

Start: Jan 2007Est. completion: Mar 201532 patients
Phase 2Completed
NCT00098553Alliance Pharmaceuticalseverolimus

Everolimus in Treating Patients With Stage IV Melanoma

Start: Apr 2005Est. completion: Feb 201053 patients
Phase 2Completed
NCT00005610Alliance Pharmaceuticalssargramostim

Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Start: Sep 2000Est. completion: Jun 200628 patients
Phase 2Completed
NCT00005875Astex Pharmaceuticalsrubitecan

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

Start: Jan 1999Est. completion: Apr 2004
Phase 2Completed
NCT00010309SanofiMART-1 antigen

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Start: Nov 2000
Phase 1/2Unknown
NCT00004025Sanofialdesleukin

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Start: Mar 199936 patients
Phase 1/2Unknown
NCT05492682Valo TherapeuticsPeptiCRAd-1

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Start: Feb 2023Est. completion: Dec 2026
Phase 1Active Not Recruiting
NCT03291002CureVacCV8102

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Start: Sep 2017Est. completion: Feb 2023
Phase 1Unknown
NCT01889420Alliance Pharmaceuticalseverolimus

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Start: Jul 2014Est. completion: Jul 20151 patients
Phase 1Terminated
NCT01176461Bristol Myers SquibbMART-1

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Start: Aug 2010Est. completion: Dec 2016127 patients
Phase 1Completed
NCT00091143Providence Therapeuticsgp100 antigen

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Start: Jul 2004Est. completion: Mar 2010
Phase 1Completed
NCT03927742Alliance PharmaceuticalsShade + app with messaging

Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors

Start: Jun 2020Est. completion: Oct 2022368 patients
N/ACompleted
NCT03518229Alliance PharmaceuticalsMicrosoft Band 2 + UV messaging

Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors

Start: Feb 2020Est. completion: May 20210
N/AWithdrawn
NCT03315468AmgenFrench Clinical Datbase of Melanoma Patients (RIC-Mel)

French Clinical Datbase of Melanoma Patients (RIC-Mel)

Start: Mar 2012Est. completion: Mar 203016,000 patients
N/ARecruiting
NCT00346008Genomicsmutation analysis

Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members

Start: Oct 2005Est. completion: Feb 20092,500 patients
N/ACompleted
NCT00049010Alliance Pharmaceuticalscomparative genomic hybridization

Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

Start: Sep 2002Est. completion: Oct 2009314 patients
N/ACompleted

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
6h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
7h ago

Executive Medical Director, Oncology Early Development

AbbVie
Florham Park, NJ
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
South San Francisco, CA
8h ago

Executive Medical Director, Oncology Early Development

AbbVie
North Chicago, IL
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 20,422 patients
13 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)